DEFA14A: Titan Merger: Black Titan Upsizes PIPE to $6M

Titan Pharmaceuticals, Inc. files a supplement to its proxy statement, updating details on its business combination with Black Titan Corporation, including an increase in the Series A Preferred Shares PIPE financing to $6 million.

Summary

• Titan Pharmaceuticals, Inc. (TTNP) filed a supplement to its definitive proxy statement for a Special Meeting of Stockholders scheduled for August 26, 2025.
• The Special Meeting is being held to approve a business combination transaction involving Black Titan Corporation (PubCo), TTNP, and TalenTec Sdn. Bhd.
• The Series A Convertible Preferred Shares Securities Purchase Agreement (PIPE) was amended on August 21, 2025, increasing the amount to be purchased from up to $4,000,000 to up to $6,000,000.
• The business combination will be accounted for as a reverse recapitalization, with TalenTec treated as the accounting acquirer for financial reporting purposes.
• Pro forma combined ordinary shares outstanding post-transaction are estimated at 9,067,942.
• TalenTec's existing security holders are expected to own approximately 54.5% of the outstanding PubCo Ordinary Shares post-transaction.
• TTNP stockholders (excluding related parties and preferred stockholders) are expected to own approximately 14.6% of PubCo Ordinary Shares post-transaction.
• Pro forma combined net loss for the six months ended January 31, 2025, is estimated at $(1,376) thousand, with a net loss per ordinary share of $(0.15).
• Pro forma combined net loss for the year ended July 31, 2024, is estimated at $(5,523) thousand, with a net loss per ordinary share of $(0.61).

Sentiment

Score: 5

Explanation: The increase in PIPE financing is positive for capital, but the pro forma financial results show significant losses, indicating a challenging financial outlook for the combined entity in the near term. The filing is primarily an an update on a complex transaction, not a performance report.

Positives

• Increased PIPE financing for Series A Preferred Shares from $4,000,000 to $6,000,000, providing additional capital for the combined entity.

Negatives

• Pro forma combined net loss for the six months ended January 31, 2025, is estimated at $(1,376) thousand.
• Pro forma combined net loss per ordinary share for the six months ended January 31, 2025, is estimated at $(0.15).
• Pro forma combined net loss for the year ended July 31, 2024, is estimated at $(5,523) thousand.
• Pro forma combined net loss per ordinary share for the year ended July 31, 2024, is estimated at $(0.61).

Risks

• The original proxy statement/prospectus contains detailed risk factors, specifically mentioned on page 41, which should be carefully considered.
• Assumptions regarding options and warrants exercise post-Business Combination, and Series A Preferred Shares conversion, if incorrect, will lead to different ownership percentages.
• The pro forma financial statements are for illustrative purposes only and are not necessarily indicative of future financial position or operating results of the Combined Company.
• Management may identify differences in accounting policies between the two entities during a comprehensive review, which could materially impact the financial statements of the Post-Combination Company.

Future Outlook

The filing provides pro forma financial information for the combined company, indicating estimated revenues of $1.683 million and a net loss of $(1.376) million for the six months ended January 31, 2025. It also projects a net loss of $(5.523) million for the year ended July 31, 2024. The Series A Preferred Shares drawdown period extends until September 30, 2026, providing potential future capital.

Industry Context

The filing details a merger in the pharmaceutical sector (Titan Pharmaceuticals) with a company (TalenTec) whose operations will comprise the ongoing operations of the combined company. This suggests a strategic shift or expansion for Titan, potentially into new markets or technologies represented by TalenTec. The increase in PIPE financing indicates continued investor interest in the combined entity's prospects, despite the pro forma losses.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or industry benchmarks to assess the results.
• The pro forma net losses suggest the combined entity will be in a growth or pre-profitability phase, which is common for pharmaceutical or technology companies undergoing significant strategic transactions.

Management Changes

Corporate Governance

Related Party Transactions

• The filing mentions 'Amounts due from a related party' and 'Amounts due to related parties' in the pro forma balance sheet, which are eliminated internally.
• TTNP Directors and Officers, including Mr. Ben-Tzvi, hold TTNP Common Stock and options.
• The Sire Group Ltd. (wholly owned by Jeffrey Chung) and Blue Harbour Asset Management L.L.C-FZ are significant stockholders.
• TalenTec shareholders (Danny Vincent Dass, Goh Chee Siong, Eddie Tan Chee Wei, Koay Chee Leong, Leow Kian Yong) are identified.
• ARC GROUP LTD is mentioned as receiving shares otherwise issuable to Eddie Tan Chee Wei.

Stakeholder Impact

• Shareholders (TTNP): Will vote on the business combination and will become shareholders of Black Titan Corporation (PubCo) post-merger, with their ownership diluted by TalenTec shareholders and PIPE investors.
• Shareholders (TalenTec): Will become majority shareholders of the combined PubCo, owning approximately 54.5%.
• Investors (PIPE): The increased PIPE financing provides a larger capital injection for the combined entity, potentially supporting future growth.
• Management/Employees: TalenTec's senior management team will comprise the senior management of the post-closing Combined Company, and TalenTec's operations will be the ongoing operations. Brynner Chiam is designated as the new CFO of Black Titan.

Next Steps

• Special Meeting of Stockholders to be held on August 26, 2025, to approve the business combination.
• Closing of the Business Combination.
• PubCo may exercise its option to sell additional Series A Preferred Shares in tranches until September 30, 2026.
• Management will perform a comprehensive review of accounting policies post-Business Combination.

Key Dates

Recommendation

The filing provides an update on a significant business combination and an increase in PIPE financing, which is a positive for capital. However, the pro forma financial statements indicate substantial net losses for the combined entity. While the merger could offer long-term strategic benefits, the immediate financial outlook suggests continued unprofitability. Investors should hold to observe the integration process and future performance of the combined company, especially given the illustrative nature of the pro forma financials and the need to assess actual post-merger results. The increase in capital is good, but the underlying business performance (as projected) is still negative.

Keywords

Titan Pharmaceuticals, Black Titan Corporation, TalenTec, Merger, Business Combination, Proxy Statement, PIPE Financing, Series A Preferred Shares, Reverse Recapitalization, SEC Filing, Corporate Governance, Shareholder Meeting